Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/288125
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Intracerebral administration of a modified antisense oligonucleotide targeting the dopamine system in a mouse model of Parkinson's disease |
Autor: | Pavia-Collado, Rubén CSIC ORCID; Miquel-Rio, Lluís CSIC ORCID; Campa, Leticia CSIC ORCID; Bortolozzi, Analía CSIC ORCID | Fecha de publicación: | 17-jul-2022 | Editor: | Cell Press | Citación: | STAR Protocols 3(2): 101445 (2022) | Resumen: | Here, we present an optimized protocol for generating a mouse model overexpressing human α-synuclein in dopamine (DA) neurons driven by an adeno-associated viral (AAV) vector and for the examination of the benefit of an antisense oligonucleotide (ASO)-based therapy on DA neurotransmission under Parkinson's disease (PD)-like conditions. We describe AAV injection, followed by implantation of an osmotic minipump for ASO delivery and a guide cannula for microdialysis to measure DA release. This protocol can be used to evaluate oligonucleotide-based therapies for PD. For complete details on the use and execution of this protocol, please refer to Alarcón-Arís et al. (2020). | Versión del editor: | http://dx.doi.org/10.1016/j.xpro.2022.101445 | URI: | http://hdl.handle.net/10261/288125 | DOI: | 10.1016/j.xpro.2022.101445 | Identificadores: | doi: 10.1016/j.xpro.2022.101445 issn: 2666-1667 |
Aparece en las colecciones: | (IIBB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
1-s2.0-S2666166722003252-main.pdf | 4,68 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
1
checked on 18-abr-2024
Page view(s)
19
checked on 18-abr-2024
Download(s)
44
checked on 18-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons